Drug Profile
Research programme: lysosomal storage disorder therapeutics - Nimbus/Takeda
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Nimbus Discovery; Shire
- Developer Nimbus Therapeutics
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for research development in Lysosomal storage diseases in USA (PO, Pill)
- 18 Mar 2015 Nimbus Discovery is now Nimbus Therapeutics